Sleep Impairment Tracks With Higher Predicted Cardiovascular and Heart Failure Risk
Sleep duration and sleep continuity are emerging as more than lifestyle variables. In this study, sleep impairment was associated with higher predicted cardiovascular risk in a large population analysis and with greater atherosclerotic burden in an experimental mouse model, drawing a clinical line between short or fragmented sleep and vascular disease biology.
The human analysis drew from 25,174 participants in NHANES and used the PREVENT equation to estimate 10-year cardiovascular risk. After adjustment for potential confounders, sleep duration showed a significant non-linear U-shaped association with the PREVENT-estimated 10-year risks of cardiovascular disease and heart failure among people without prior cardiovascular disease, using 7–8 hours per night as the reference group. In plain clinical terms, both too little sleep and too much sleep tracked with worse predicted risk. The relationship did not extend in the same way to estimated 10-year atherosclerotic cardiovascular disease risk, which stayed nonsignificant.
One result stands out immediately. The sleep-risk curve was not linear.
Population Risk Rose at Both Ends of the Sleep Curve
That U-shaped pattern matters because it argues against a simple threshold model in which only sleep deprivation drives vascular harm. A more plausible interpretation is that sleep duration is acting as a marker for broader physiologic stress, altered autonomic tone, inflammatory burden, metabolic dysregulation, or underlying illness that also influences cardiovascular prediction models. The PREVENT equation captures more than one vascular pathway, including heart failure risk, so the pattern may reflect sleep-related effects on hemodynamics and myocardial stress rather than a single plaque-centered mechanism.
The absence of a significant association with estimated atherosclerotic cardiovascular disease risk is just as informative. It suggests that sleep may influence cardiovascular risk through pathways beyond classic atherothrombosis alone, especially those relevant to heart failure biology. Endothelial dysfunction, sympathetic activation, altered blood pressure patterns, and impaired recovery physiology are all biologically plausible routes by which sleep disruption could worsen cardiovascular prognosis without necessarily showing the same signal in a narrower atherosclerotic estimate.
This distinction is clinically useful at the bedside. A patient with poor sleep may carry risk that is not fully explained by lipids, blood pressure, or glycemic status alone.
Fragmented Sleep Increased Plaque Burden in Mice
The animal work strengthened the epidemiologic signal by moving from association to mechanism-adjacent biology. Investigators created a chronic sleep-fragmentation model in C57BL/6J mice using fragmented light-dark cycles, then assessed atherosclerosis progression histologically in ApoE-/- mice. In those experimental models, chronic sleep fragmentation was associated with increased atherosclerotic plaque burden.
The mouse data are especially notable because serum biochemical parameters did not change appreciably. In other words, the plaque signal appeared without an obvious parallel shift in routine circulating chemistry. That pattern raises the possibility that sleep fragmentation was acting through local vascular inflammatory pathways, immune-cell trafficking, circadian disruption, or endothelial injury rather than through broad changes that would be captured by standard serum testing. In atherosclerosis, those mechanisms can matter early, before conventional laboratory markers move.
For clinicians, this is the more unsettling part of the story. Sleep fragmentation may worsen vascular disease while leaving routine blood tests deceptively ordinary.
Why Sleep Biology Fits Atherosclerotic Progression
Atherosclerosis is not driven only by cholesterol deposition. It is also shaped by chronic low-grade inflammation, vascular repair failure, oxidative stress, and neurohormonal activation. Fragmented sleep can plausibly worsen all of these. Repeated interruption of normal sleep architecture may increase sympathetic drive and disturb circadian regulation, both of which can influence blood pressure variability, metabolic homeostasis, and inflammatory signaling. Over time, those shifts may accelerate plaque accumulation or destabilize the vascular environment in which plaques develop.
The findings also fit with the growing recognition that sleep health is a cardiovascular variable in its own right. Short sleep and sleep fragmentation are common in modern life, but they are often treated as symptoms rather than modifiable exposures. This study argues for a more active clinical stance. Sleep history belongs in cardiovascular risk assessment, particularly when traditional risk factors do not fully explain the patient’s profile.
The strongest translational message is not that sleep replaces standard prevention. It is that sleep adds another layer of risk assessment that can be modified.
What the Study Can and Cannot Prove
The human component was observational, so it cannot prove that changing sleep duration will reduce future cardiovascular events. The analysis also used estimated 10-year risk, not adjudicated outcomes. That means the study informs prediction and association rather than clinical event reduction. Even so, the sample size was large, the adjustment was extensive, and the non-linear pattern was consistent enough to deserve attention.
The animal component adds biologic plausibility, but mouse atherosclerosis does not map perfectly onto human disease. Fragmented light-dark cycles are a useful experimental proxy for sleep disruption, yet they cannot reproduce every social, behavioral, and medical factor that shapes sleep in patients. Serum chemistry also may miss tissue-level inflammation or vascular remodeling. Those constraints do not weaken the central signal so much as define the next questions: which sleep phenotype matters most, which cardiovascular pathways are most sensitive, and whether improving sleep continuity changes vascular biology in a measurable way.
For now, the practical implication is straightforward. Sleep impairment should not be treated as a background complaint when cardiovascular risk is being assessed. It may be part of the risk itself, especially when heart failure prediction appears to move in step with both short and prolonged sleep and when experimental sleep fragmentation enlarges plaque burden without obvious changes in standard serum markers.